Wednesday, July 15, 2026

11:15 AM - 1:15 PM

---

Details

Nitric oxide and natriuretic peptide -sensitive guanylyl cyclases (GCs) are cyclic guanosine-3’,5’-monophosphate (cGMP)-generating catalytic receptors that play key, complimentary roles in regulating cardiac and vascular homeostasis. Contemporary advances in the understating of the physiological and pathophysiological function(s) of GCs have led to the development of a number of new medicines targeting this family of enzymes for the treatment of a wide variety of cardiovascular diseases, including erectile dysfunction, pulmonary hypertension (PH), heart failure with reduced (HFrEF) and preserved (HFpEF) ejection fraction, and cardiometabolic disease. This symposium will comprise internationally-leading experts in the field who will update on cutting-edge advances in the pre-clinical and clinical arena, with respect to both elucidating novel GC-dependent signalling pathways in the cardiovascular system and new GC-targeted therapies for cardiac and vascular disorders.

---

Session chair